STAAR Surgical Tops 4 Million ICL Sales, Driving Shift from Laser Procedures
STAAR Surgical has sold over 4 million implantable collamer lenses globally, marking a major adoption milestone for its EVO ICL portfolio. This record underscores a sustained industry shift from laser-based procedures toward ICL solutions, potentially boosting recurring lens revenue and expanding its addressable market.
1. Global ICL Sales Milestone
STAAR Surgical has sold over 4 million implantable collamer lenses worldwide since launching its EVO ICL platform, marking a significant growth trajectory in refractive surgery adoption.
2. Shift from Laser-Based Corrections
The milestone reflects a growing preference for ICLs over laser-based techniques such as LASIK and PRK due to ICL’s reversible nature and broad range of treatable refractive errors.
3. Financial and Market Impact
Repeated lens purchases and procedure volumes underpin recurring revenue streams, with the addressable market expanding as surgeons integrate ICL options into their practices.
4. Future Growth Prospects
STAAR Surgical plans to support further adoption through ongoing clinical studies, product refinements and regulatory clearances in new markets, targeting sustained double-digit ICL sales growth.